Evidence map›Paper›PMID 34814157›Full record

ArticleUrologia internationalis2022

Decision Regret and Quality of Life after Focal Therapy with Vascular-Targeted Photodynamic Therapy (TOOKAD®) for Localized Prostate Cancer.

Luka Flegar, Martin Baunacke, Bjoern Thorben Buerk, Rick Proschmann, Aristeidis Zacharis, Stefan Propping, Johannes Huber, Christian Thomas, Angelika Borkowetz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Urologia internationalis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Luka FlegarDepartment of Urology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Martin BaunackeDepartment of Urology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Bjoern Thorben BuerkDepartment of Urology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Rick ProschmannDepartment of Urology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Aristeidis ZacharisDepartment of Urology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Stefan ProppingDepartment of Urology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Johannes HuberDepartment of Urology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Christian ThomasDepartment of Urology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Angelika BorkowetzDepartment of Urology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim of the study was to assess quality of life (QoL), decision involvement, and decisional regret after treatment with vascular-targeted photodynamic therapy (VTP) (TOOKAD®) for unilateral low-risk prostate cancer.

methodsValidated questionnaires (EORTC QLQ-C30 and QLQ-PR25) capturing QoL post-treatment, involvement in decision-making (Control Preferences Scale) and decision regret (Decisional Regret Scale), were given to patients at the 12-month visit after undergoing VTP at our institution between May 2018 and February 2021.

resultsOut of 44 patients, 36 patients were included in this study and 31 (86.1%) responded to the questionnaires. Mean overall health score capturing QoL at 12 months was 79.3 (standard deviation: ±18.1). 70.9% of the patients (n = 22) had no decision regret, and 67.8% of men (n = 21) had an active role in decision-making. In control biopsy at 12 months post-treatment, 19.4% of patients (n = 7) presented with local recurrence and progression to higher Gleason score (GS) was found in 13.8% of patients (n = 5). Patients (n = 3) presenting with tumor recurrence or progression to higher GS in control biopsy showed a significantly higher level of decision regret (p < 0.009).

conclusionOnly 9.7% of men (n = 3) felt a strong emotion of regret at 12 months after VTP. Level of decision regret was significantly higher in patients with local recurrence or tumor progression detected in control biopsy. QoL was stable after VTP.

Indexed as

PhotochemotherapyProstatic NeoplasmsBacteriochlorophyllsDecision MakingEmotionsHumansMaleQuality of LifeBacteriochlorophyllspalladium-bacteriopheophorbideDecisional regretFocal therapyProstate cancerQuality of lifeTOOKAD®Vascular-targeted photodynamic therapy

Identifiers

PMID34814157
PMCPMC9533463

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.